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Glucocorticoids are commonly used in treating diseases with white matter lesions, including demyelinating diseases and spinal cord
injury (SCI). However, glucocorticoids are ineffective in gray matter injuries, such as head injury and stroke. The differential glucocor-
ticoid effects in white and gray matter injuries are unclear. We report here a novel mechanism of methylprednisolone (MP), a synthetic
glucocorticoid widely used for treating multiple sclerosis and SCI, in protecting oligodendrocytes (OLGs) against AMPA-induced exci-
totoxicity,whichhasbeen implicated in thewhitematter injuries anddiseases. The cytoprotective actionofMP inOLGs is causally related
to its upregulation of a neuroprotective cytokine erythropoietin (Epo). MP transactivation of Epo expression involves dual transcription
factors: glucocorticoid receptor (GR) and hypoxia-inducible factor-1 (HIF-1). Coimmunoprecipitation, chromatin immunoprecipi-
tation analysis, yeast two-hybrid analysis, and structure modeling of three-dimensional protein–protein interactions confirm that MP
induces interaction between GRDNAbinding domain andHIF-1 PAS domain, with subsequent recruitment of HIF-1 to transactivate
Epo expression in OLGs. In contrast, MP activates GR but does not induce GR–HIF-1 interaction, HIF-1 binding to Epo enhancer/
promoter, or Epo expression in cultured cortical neurons. The OLG-specific GR–HIF-1 transactivation of Epo provides novel insights
into the development of more effective therapies for diseases affecting the white matter.
Introduction
Neuroprotective strategies for treating CNS disorders have been
directed mostly at preserving gray matter or neurons (Lipton,
2006). However, white matter injuries, as seen in demyelinating
diseases, includingmultiple sclerosis (MS) and spinal cord injury
(SCI), may have an even greater impact on functional outcomes
(Bradbury et al., 2002; Stys and Lipton, 2007). For example, dis-
ability after SCI is primarily caused by the white matter lesion
(Wrathall et al., 1994; Crowe et al., 1997). Gray matter injury,
sparing most white matter (e.g., central cord syndrome), results
in segmental motor/sensory dysfunction. Disability after SCI can
be mostly ascribed to injury to the white matter, which contains
the long tracts. Death of oligodendrocytes (OLGs), which form
myelin sheath and maintain long tract function in the CNS, is a
prominent pathological feature in demyelinating diseases and
SCI (Crowe et al., 1997;Miller andMi, 2007). OLG death in these
disorders results, in part, from excitotoxicity involving AMPA
receptor (McDonald et al., 1998; Smith et al., 2000;Miller andMi,
2007). AMPA receptor antagonism is effective in salvaging white
matter after traumatic or ischemic SCI (Wrathall et al., 1994;
Kanellopoulos et al., 2000).
Glucocorticoids (GCs), primarilymethylprednisolone (MP), are
the mainstay in treating patients with diseases affecting the white
matter, includingMS and SCI (Bracken et al., 1990; Zivadinov et al.,
2001; Chataway et al., 2006). GCs regulate transcriptional events by
activating glucocorticoid receptor (GR), which binds to glu-
cocorticoid response element (GRE) or interacts with other
transcription factors to regulate gene expression (Becker et al.,
1986). GR modulation of inflammatory/immune or oxidative
processes are the proposed mechanisms of MP action in de-
myelinating diseases and SCI (Schmidt et al., 2000; Xu et al.,
2001a; Tsutsui et al., 2008). However, GC or antioxidant ther-
apies were ineffective in gray matter injuries, such as head
trauma or stroke (Edwards et al., 2005; Diener et al., 2008).
The mechanism underlying preferential effects of GCs in the
white, but not gray, matter remains to be defined.
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MP upregulates antiapoptotic Bcl-xL gene expression to pro-
tect OLGs against AMPA-induced death in vitro and in a rat SCI
model in vivo (Lee et al., 2008). Bcl-xL expression is also upregu-
lated by erythropoietin (Epo)/Epo receptor (Silva et al., 1999).
Epo is effective in animal models of SCI and MS (Gorio et al.,
2002; Li et al., 2004). Epo upregulation involves activation of
hypoxia-inducible factor-1 (HIF-1) (Semenza et al., 1991; Liu
et al., 2005), a member of the PAS (PER/ARNT/SIM) family of
basic helix–loop–helix (bHLH) transcription factors essential in
hypoxia sensing for cell survival (Sharp and Bernaudin, 2004;
Semenza, 2009). During activation, HIF-1 translocates into the
nucleus and heterodimerizes with aryl hydrocarbon receptor nu-
clear translocator (ARNT), also known as HIF-1, to bind to
hypoxia-responsive elements (HRE) in the 3 enhancer of theEpo
gene to induce Epo expression (Semenza et al., 1991).
We report here Epo transactivation involving GR and HIF-1
interaction is a causal mechanism ofMP protection of OLGs, but
not neurons, against AMPA excitotoxicity. These findings offer
novel insights into the development of innovative therapies for
white matter diseases.
Materials andMethods
Animals. Sprague Dawley rats were obtained from the National Institute
of Experimental Animal Research (Taipei, Taiwan). Animals were killed
by an overdose of sevoflurane tominimize pain or discomfort. All animal
experimentation procedures were approved by the Experimental Animal
Review Committee at Taipei Medical University and are in accordance
with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals.
Cell cultures. OLGs in culture were prepared from postnatal day 0–2
neonatal rat brains (Xu et al., 2001b; Lee et al., 2004). OLG purity was
90% based on receptor interacting protein (RIP) immunoreactivity
(Xu et al., 2001b; Lee et al., 2004). Cortical neurons were prepared from
fetal rat brains at embryonic day 17 as described previously with85%
cells in culture expressing the neuronal marker MAP-2 (Lee et al., 2008).
Cortical neurons at 10 d in vitro (DIV) that express GR were used in this
study.
Quantitative real-time and semiquantitative reverse transcription-PCR.
TotalRNAextraction, cDNApreparation, and reverse transcription (RT)-PCR
were as described previously (Lee et al., 2008). The real-time PCR reaction
was performed using an ABI PRISM 7300 Sequence Detection System. The
semiquantitative PCR of Epo,Nr3c1 (GR),Hif1a (HIF-1), Arnt (HIF-1),
andBcl-xL cDNAswasperformedusing the followingprimers, and cDNAof
a reference gene Gapdh (glyceraldehyde-3-phosphate dehydrogenase) was





GGTCTGCTGGAATC-3; Arnt (HIF-1) 5-CTGTTGTCCAGAGGG-
CTATTAAG-3 and 5-CAAGTCTCTCTTTATCGGCAGAG-3; Bcl-xL,
5-AGGCTGGCGATGAGTTTGAA-3 and 5-TGAAACGCTCCTGGC-
CTTTC-3; and Gapdh, 5- GACCCCTTCATTGACCTCAAC-3 and 5-
GATGACCTTGCCCACAGCCTT-3.
SCI animal model. SCI was conducted using a New York University
Impactor (Hashimoto et al., 2007) to injure rat spinal cord at T9–T10
(Lee et al., 2008). Sprague Dawley rats (9 weeks old) were randomly
divided into three groups: the sham control, SCI, and SCI with MP
treatment groups. Vehicle or MP (30 mg/kg body weight) was adminis-
tered intravenously 30 min after SCI. Four and 24 h after treatment,
animals were anesthetized, and a 1 cm segment of the injured cord cen-
tering at the injury epicenter or corresponding sham-operated cord tis-
sue was collected for quantitative real-time RT-PCR analysis.
Western blot analysis. Western blot analysis was performed as de-
scribed previously (Xu et al., 2001b; Lee et al., 2008). Primary antibodies
used were rabbit anti-Bcl-xL (1:500; Santa Cruz Biotechnology), rabbit
anti-GR (1:500; Santa Cruz Biotechnology), mouse anti-HIF-1 (1:500;
Novus), mouse anti-HIF-1 (1:1000; Millipore Bioscience Research Re-
agents), and mouse anti-GAPDH (1:5000; Biogenesis) antibodies. The
immune complex was visualized using HRP-reactive ECL reagents (GE
Healthcare).
RNA knockdown.OLGs were transfected with a set of siRNAs specific for
GR,HIF-1,HIF-1, Epo, or scrambledRNA(Silencer Predesigned siRNA;
Ambion) using Lipofectamine reagent (Invitrogen). The siRNA sequences
were as follows: GR (Nr3c1; GenBank accession number NM_012576), 5-
GGUUGCUUAAAGAAAGUUtt-3 (exon 9) and 5-GCUACAGUCAA-
GGUUUCUGtt-3 (exon 1); HIF-1 (Hif1a; GenBank accession number
NM_024359), 5-GCUUGCUCAUCAGUUGCCAtt-3 (exon 2) and 5-
CCAGUUGAAUCUUCAGAUtt-3 (exon 9); HIF-1 (Arnt; GenBank ac-
cession number NM_012780), 5-GGCUGGAUUUUGAUGAUGAtt-3
(exon 2) and 5-CGGCCUACAUUGUCUAACAtt-3 (exon 15); and Epo
(GenBank accession number NM_017001), 5-GGAGGCAGAAAAUGU-
CACAtt-3 (exon 2) and 5-GGCUGUAGAAGUUUGGCAAtt-3 (exon 4).
Five hours after transfection, the Lipofectamine-containing medium was
replacedwithOLGculturemediumtoallowcells to recover for another67h.
Luciferase activity assay. Three copies of human EPO gene enhancer
(HREEPO)-containing sequences, 5-ATAGGTACCGCCCTACGTGC-
TGTCTCAGCCCTACGTGCTGTCTCAGCCCTACGTGCTGTCTCA-
GCTAGCTAT-3, were cloned into promoter of pGL2 promoter vector
(Promega) to obtain the luciferase reporter construct pHREEPO–Luc.
The cells were transfected with pHREEPO–Luc and pRL–TK (Promega)
in Lipofectamine for 36 h, followed by treatments with various agents for
24 h, and then harvested for the luciferase activity assay using the Dual-
Luciferase reporter assay system (Promega).
Coimmunoprecipitation.Nuclear fraction of OLGs was extracted using
NE-PERNuclear andCytoplasmic ExtractionReagents (Pierce). Nuclear
proteins (50 g) were incubated with mouse anti-GR antibody (2 g;
Abcam) or mouse anti-HIF-1 antibody (2 g; Novus) for 12 h at 4°C,
followedwith protein G Sepharose for 1 h at 25°C. The immune complex
was then washed and dissociated according to the Protein G Sepharose 4
Fast Flow protocol (GE Healthcare). Dissociated immune complex was
then subjected to Western blotting using rabbit anti-GR (1:500; Santa
Cruz Biotechnology), mouse anti-HIF-1 (1:500; Novus), and mouse
anti-HIF-1 (1:500;Millipore Bioscience ResearchReagents) antibodies,
respectively.
Yeast two-hybrid assay. Yeast two-hybrid assay was performed as de-
scribed previously with minor modifications (Wang et al., 2004). The
plasmid pGBKT7–mHIF-1 PAS-B was constructed by cloning a PAS
domain (amino acids 238-346) of HIF-1 into pGBKT7 (Clontech).
pGADT7–GR–DNA binding domain (DBD) (amino acids 436-516) and
pGADT7–GR–ligand binding domain (LBD) (amino acids 601-751)
were cloned by insertingDNA fragments ofGRderived frompcDNA3.1–
rGR (pcDNA3.1–rGR kindly provided by Dr. Trevor K. Archer, LMC,
National Institute of Environmental Health Sciences, National Institutes
of Health, Research Triangle Park, NC) between the NdeI and XhoI sites
of pGADT7 (Clontech). Y190 cells were cotransformed with GAL4AD–
GR–DBD (pGADT7–GR–DBD) and GAL4BD–HIF-1 PAS-A
(pGBKT7–HIF-1 PAS-A) or with GAL4AD–GR–LBD (pGADT7–GR–
LBD) and GAL4BD–HIF-1 PAS-B (pGBKT7–HIF-1 PAS-B) based
plasmids. The transformed cells were plated onto a 25 mM 3-amino-
1,2,4-triazole (3-AT) containing SD medium (Synthetic Dropout)
lacking tryptophan, histidine, and leucine. Five independent colonies
were inoculated to examine -galactosidase activity using o-nitrophenyl-
-D-galactopyranoside as the substrate with A420nm measured in the
liquid culture assay. The -galactosidase unit was calculated by the fol-
lowing equation: -galactosidase units  1000  A420/(t  V  A600),
where t is elapsed time (minutes) of incubation, V is 0.1 ml  concen-
tration factor, and A600 the density of yeast culture.
Chromatin immunoprecipitation assay (Lin et al., 2008). Antibodies
used for immunoprecipitation were mouse anti-GR (2 g; Abcam),
mouse anti-HIF-1 (2 g; Novus), and rabbit anti-CREB (cAMP re-
sponse element-binding) protein binding protein (CBP) (2 g; Santa
Cruz Biotechnology) antibodies. Immune complex-bound DNA was
purified using a PCR purification kit (Qiagen) and amplified by quanti-
tative PCR (Applied Biosystems) with primers flanking an HRE-
containing Epo gene 3 enhancer fragment: (3497 to3618; GenBank
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accession number NM_017001) 5-TACCTCCCCCCCCCCCCA-
TTCTGGT-3 and 5-CAAGCCCAGAGGGGTCAAGAGGTCAGA-3.
Primers flanking an Epo gene promoter fragment (375 to 221;
GenBank accession number NM_017001) were 5-CAGCCTGCTCTAC-
CCCAGCAAGGA-3 and 5-GGGGGTCGGGGATGTTATCAGCA-3.
Primers flanking a GRE-containing Trh (thyrotropin releasing hor-
mone) gene promoter fragment (267 to 71; GenBank accession
number NM_013046) were 5-CGCGGACTACTCCCGGGACGT-
CTCT-3 and 5-GGGGAGGGGGCGCAGGCCGAAGACA-3. Normal
mouse IgG served as the control.
Computermodeling of protein–protein interaction.The structures ofGR
and HIF-1 were obtained as described below for the predictive struc-
tural analysis of GR–HIF-1 interaction. For GR, the structure of GR–
DBD (amino acids 439-510) is available [Protein Data Bank (PDB)
identification number 1GDC], and GR–LBD (amino acids 519-795) was
generated by SWISS-MODELRepository (Schwede et al., 2003) using the
protein template PDB identification numbers 1 NHZ, 1M2Z, and 1P93.
No crystal structure information of HIF-1 is available. We used con-
served domain search of National Center for Biotechnology Information
BLASTp (protein–protein basic local alignment search tool) for sequence
domain analysis. The PAS-B domain of HIF-1 was predicted by se-
quence homology (PDB identification numbers 1P97, A24A, A24B,
1XO0, and 1WA9). Furthermore, fold recognition and three-
dimensional annotation were conducted to obtain a predicted three-
dimensional structure. Prediction of interactions of the GR–DBD and
GR–LBD with the PAS-B domain of the HIF-1 was then performed
using the program GRAMM (Vakser, 1996). In addition, we predicted
the interaction of HIF-1 and HIF-1 using the crystal structures of
HIF-2–ARNT PAS-B domain complex (PDB identification number
2A24) as a template, followed by predicting the interaction of GR–DBD
andGR–LBDwith theHIF-1–HIF-1 complex. Finally, theDNAbind-
ing capability of GR–DBD in docking into the HIF-1 or HIF-1–
HIF-1 complex was predicted.
Statistic analysis. Data were expressed as means  SEM. Statistical
analysis was performed by one-way ANOVA, followed by Newman–
Keuls multiple comparison post hoc test to compare all groups with the
control group or to compare designated pairs of groups. p 	 0.05 was
considered significant.
Results
MP upregulation of Epo expression in OLGs but not
cortical neurons
We noted in a recent study that neuroprotective effect of MP is
restricted to OLGs, but not neurons, in the injured spinal cord
(Lee et al., 2008). MP or other GCs are effective in treating white
(Zivadinov et al., 2001; Chataway et al., 2006), but not gray (Ed-
wards et al., 2005; Diener et al., 2008), matter diseases. Epo has
similar effects in SCI (Gorio et al., 2002; Vitellaro-Zuccarello et
al., 2007) and the white matter diseases (Li et al., 2004). These
findings suggestMP and Epomay share a common neuroprotec-
tive mechanism. Figure 1A shows that MP upregulated Epo
mRNA expression in OLGs, but not neurons, based on semi-
quantitative (top panel) and quantitative (bottom panel) RT-
PCR analysis. Epo transactivation has been shown to involve
HIF-1, a cytoprotective transcription factor, inducible by hyp-
oxia (Semenza et al., 1991; Sharp and Bernaudin, 2004; Semenza,
2009). Cobalt chloride (CoCl2) activates HIF-1, mimicking
hypoxia.WhereasMP failed to upregulate Epo expression in neu-
rons, chemical hypoxia induced by CoCl2 was effective in neu-
rons as well as OLGs (Fig. 1A, top panel). This finding suggests
that neuronal cultures used in the present study maintain a
hypoxia-inducible response for upregulating Epo expression but
do not share MP responsiveness noted in OLGs. The ELISA re-
sults show thatMP increased the Epo protein content in OLGs in
a dose-dependent manner with an EC50 of 83.11 nM (Fig. 1B).
MP upregulation of Epo expression in the injured spinal cord
in vivo
We further examined whether MP treatment affects Epo gene
expression in the injured spinal cord in rats. Figure 1C showsMP
upregulation of Epo mRNA expression in the spinal cord 4 and
24 h after injury with a dosing schedule (intravenous MP, 30
mg/kg bodyweight given 30min after insult) that has been shown
to reduce the extent of OLG apoptosis and white matter damage
after SCI (Lee et al., 2008). Results suggest that MP-induced Epo
expression occurs not only in cultured OLGs in vitro but also in
the injured spinal cord in vivo.
Causal role of Epo expression inMP protection of OLGs
against excitotoxicity
To establish the causal role of Epo expression inMP protection of
OLGs against excitotoxicity, we first studied whether exogenous
Figure 1. MP upregulation of Epo expression in OLGs and injured spinal cord but not neu-
rons.A, OLGsand10DIV cortical neuronswere treatedwithMP (1M)or CoCl2 (0.4mM) for 12h,
followed by RNA extraction. EpomRNA was analyzed by semiquantitative (top) and quantita-
tive real-time (bottom) RT-PCR, in which Gapdh and-actinmRNA served as internal controls,
respectively. B, Dose–response effect of MP in inducing Epo expression in OLGs was measured
by ELISA at 24 h. C, MP (30mg/kg bodyweight, i.v.) was given 30min after SCI. The spinal cord
tissues harvested 4 and 24 h after SCI were subjected to quantitative real-time RT-PCR for
assessing the extent of Epo mRNA expression. The Ct value was normalized and expressed
relative to the sham-operated control (Sham). Data are expressed asmeans SEM (n 4 inA
andB; n 5 in C). *p	 0.05, **p	 0.01 versus the control (Ctrl) (A), the 0MMP group (B),
or the SCI group (C) by one-way ANOVA andNewman–Keulsmultiple comparison post hoc test.
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Epo shares a similar cytoprotective action
as MP in OLGs. Both EPO (Silva et al.,
1999) andMP (Xu et al., 2009) engage the
JAK/STAT5 pathway in upregulating Bcl-
xL, an antiapoptotic gene. Both human re-
combinant EPO (rhEPO, 40 ng/ml) and
MP upregulated Bcl-xL expression in
AMPA-treated OLGs (Fig. 2A), sharing a
common cytoprotective mechanism. Ap-
plication of rhEPO also protected OLGs
against AMPA-induced death (Fig. 2B).
To confirm the causal role of Epo expres-
sion in MP protection of OLGs, we ap-
plied Epo small interfering (si) RNA
(siEpo) to knockdown Epo expression
(Fig. 2C, inset). The cytoprotective action
of MP was abolished in OLGs transfected
with siEpo but not scrambled RNA (Fig.
2C). These findings support the conten-
tion that Epo expression is causally related
to MP protection of OLGs against AMPA
excitotoxicity.
GR-dependent activation of HIF-1
by MP
Transactivation of Epo gene entails the ac-
tivation of HIF-1 to bind to HRE in the
3 Epo enhancer region (Semenza et al.,
1991). Therefore, we examined whether
MP upregulation of Epo expression is me-
diated by HIF-1 activation. We estab-
lished a luciferase reporter construct by
inserting an HRE-containing DNA frag-
ment of the Epo gene enhancer into a
pGL2-promoter vector (pHREEPO–Luc)
to study the effect of MP on Epo expres-
sion in relation to HIF-1 activity.
Treatment with 1 M MP increased
HREEPO-driven luciferase activity in OLGs but not neurons
(Fig. 3A), whereas chemical hypoxia (CoCl2) induced a similar
degree of HREEPO-driven luciferase activity in both cell types
(Fig. 3B), confirming that this expression construct is responsive
to an establishedHIF-1 activationmechanism. Figure 3C shows
that dexamethasone, a potent GR agonist, increased HREEPO-
driven luciferase activity, comparable with MP. Non-GC ste-
roids, such as aldosterone, a mineralocorticoid receptor (MR)
agonist, or 17-estradiol, an estrogen receptor agonist, were
without effects. GR-dependent action of MP was further con-
firmed by the findings that RU486 [11-[p-(dimethylamino)
phenyl]-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one] (a
GR antagonist), but not spironolactone (anMR antagonist), was
effective in blocking MP activation of HIF-1 at the basal level
(Fig. 3D) or after AMPA treatment (Fig. 3E).
Reversal ofMP activation of pHREEPO–Luc andupregulation of
Epo expression byGRorHIF-1 knockdown
To confirm the causal role of GR and HIF-1 in Epo expression
and subsequent Bcl-xL upregulation byMP, we transfectedOLGs
with specific siRNAs against Nr3c1 (siGR) or Hif1a (siHif1a) to
knockdown GR and HIF-1 expression, respectively. Both
mRNA and protein levels of GR and HIF-1 were reduced by
their specific siRNA (supplemental Fig. 1A,B, available at www.
jneurosci.org as supplemental material). To verify that siHif1a
indeed reduces HIF-1 at the protein level, we used a strategy
reported previously (Siddiq et al., 2009) to confirm the knock-
down efficiency of siHIF1a in hypoxia-treated OLGs (supple-
mental Fig. 1C, available at www.jneurosci.org as supplemental
material). GR or HIF-1 knockdown abolishedMP activation of
pHREEPO–Luc (Fig. 4A), MP upregulation of Epo (Fig. 4B) and
Bcl-xL (Fig. 4C), and the protective effect of MP against AMPA-
induced cell death in OLGs (Fig. 4D). HIF-1 knockdown even
accentuated AMPA excitotoxicity (Fig. 4D). These results sup-
port the causal role of GR and HIF-1 in mediating the cytopro-
tective action of MP via upregulation of Epo expression in OLGs.
MP enhancement of nuclear GR–HIF-1 interaction in OLGs
GR may regulate gene expression by interacting with other tran-
scription factors (Xu et al., 2009). We explored whether GR in-
teracts with HIF-1 directly in MP transactivation of Epo gene
expression. The blotting pattern of HIF-1, verified by CoCl2
(supplemental Fig. 1C, available at www.jneurosci.org as supple-
mental material), was used to identify HIF-1 in the coimmuno-
precipitation (co-IP) study. MP treatment increased nuclear
HIF-1 accumulation in OLGs but not neurons (Fig. 5A). The
GR content in the nuclear fraction was increased in OLGs as well
as neurons afterMP treatment (Fig. 5B). However, an increase in
GR–HIF-1 interaction after MP treatment was noted only in
OLGs but not neurons when immunoprecipitating the nuclear
Figure 2. Epo and MP in AMPA-induced OLG death. A, OLGs were treated with AMPA (100M) supplemented with cyclothia-
zide (25M) (referred to as AMPA hereafter) with rhEPO (4 U/ml, 40 ng/ml) (left) or MP (right) for 24 h, followed by Western
blotting for Bcl-xL. B, rhEPO effect on OLG viability after AMPA treatment based on MTT assay. C, EpomRNA expression after OLG
transfection with scrambled RNA (Scr) or siRNA specific for rat EpomRNA (siEpo) (top). Effects of Scr or siEpo transfection on MP
protection of OLGs against AMPA cytotoxicity (bottom). *p	 0.05, **p	 0.01 versus the control group; #p	 0.05 versus the
AMPA-treated group. NS, No significant difference between the two groups (n 4).
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protein extracted from the MP-treated cells with a GR antibody
and blotting with an HIF-1 antibody (Fig. 5B). The MP-
increased GR–HIF-1 interaction in OLGs was further verified
by using immunoprecipitation with an HIF-1 antibody and
blotting with a GR antibody (see Fig. 7B).
This result is in agreement with previous
findings that MP transactivates Epo ex-
pression only in OLGs but not neurons.
Co-IP of two proteins can result from
either direct or indirect interaction. We
conducted yeast two-hybrid analysis to
explore possible direct interaction be-
tween GR and HIF-1. Based on the do-
main maps of GR and HIF-1 (Fig. 5C),
we examined the interactions between
GR–LBD and GR–DBD, respectively,
with the HIF-1 PAS-A (amino acids 85-
153) and PAS-B (amino acids 238-346)
domains. The GR–DBD, but not the GR–
LBD, yielded appreciable number of colo-
nies when hybridized with the HIF-1
PAS-A or PAS-B domain (Fig. 5D). Re-
sults suggest that the GR–DBD, but not
the GR–LBD, directly interacts with the
HIF-1 PAS domains.
Co-recruitment of HIF-1 and GR onto
the promoter and 3 enhancer of the
Epo gene in OLGs but not neurons
Because MP induces GR–HIF-1 interac-
tion (Fig. 5), we examined whether the
GR–HIF-1 complex is recruited to the
promoter or/and 3 enhancer of the Epo
gene during MP treatment. Chromatin
immunoprecipitation (ChIP) analysis
was performed by immunoprecipitating
nuclear HIF-1 or GR, followed by PCR
amplification of promoter fragments
spanning from 375 to 221 and HRE-
containing 3 enhancer fragments span-
ning from 3497 to 3618 of the Epo
gene, respectively (Fig. 6A). Preferential
effects of MP on the GR–HIF-1 associa-
tion with the Epo promoter and enhancer
were observed in OLGs (Fig. 6B) com-
pared with neurons (Fig. 6C). In OLGs
but not neurons, the association of
HIF-1 and GR to the Epo promoter was
increased to threefold at 1 and 3 h after
MP treatment (Fig. 6B). Interestingly, GR
and HIF-1 binding to the 3 enhancer
was not significant until 3 h after MP
treatment, when2.5-fold and 7-fold in-
crease was noticed compared with basal
binding activity (0 h), respectively. In
neurons, HIF-1 had a slight and tran-
sient association with the Epo enhancer
afterMP treatment. No significant associ-
ation of HIF-1 with the promoter was
observed in neurons. More importantly,
no significant GR binding to either the
promoter or 3 enhancer was noted in
neurons (Fig. 6C). As a positive control,
MP-induced GR binding to a GRE-containing fragment in the
promoter of Trh, an established GC-responsive gene, was exam-
ined in both OLGs and neurons. As shown in Figure 6D, MP
induced GR binding to GRE to a similar extent in both cell
Figure 3. MP effect on HREEPO-driven luciferase activity in OLGs. OLGs or neurons were cotransfected with pHREEPO–Luc and
pRL–TK for 36 h before the respective treatments, followed by the luciferase activity assay. A, OLGs and neurons were with or
without MP (1M) treatment for 24 h. B, OLGs and neurons were treated with CoCl2 (0.4 mM) for 24 h. Note that both OLGs and
neurons are responsive to chemical hypoxia induced by CoCl2. C, OLGs were treated with steroids, including MP, dexamethasone
(Dex), aldosterone (Ald), and 17--estradiol (E2), 1 M each for 24 h. D, OLGs were pretreated with 1 M RU486 (RU; a GR
antagonist) or spironolactone (SP; anMR antagonist) for 30min, followedbyMP (1M) for 24h.E, OLGswere pretreatedwith RU486
(1M) for 30min, followedbyAMPAwith orwithoutMP. **p	 0.01 versus vehicle-treated control (Ctrl) (n 4).
Figure 4. HIF-1 and GR knockdown on MP-induced HREEPO enhancer activity and Epo/Bcl-xL expression. OLGs were trans-
fectedwith scrambled siRNA (Scr), siNr3c1 (for GR), or siHif1a (for HIF-1) for 72 h, followed by:A, transfectionwith pHREEPO–Luc
for 24 h and thenMP (1M) treatment for 24 h, followed by luciferase activity assay; B, quantitative real-time RT-PCR analysis of
EpomRNA; C, semiquantitative RT-PCR analysis of Bcl-xL mRNA; D, AMPA treatment with or without MP (1M) for 24 h for cell
death analysis by LDH release assay. *p	 0.05, **p	 0.01 versus vehicle-treated control (Ctrl); #p	 0.05 versus the AMPA-
treated group (n 4).
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types. These findings suggest that co-
recruitment of HIF-1 and GR to the Epo
promoter/enhancer occurs in OLGs but
not in neurons. The association of GR and
HIF-1 with the Epo promoter and en-
hancer in OLGs appears sequential, oc-
curring at 1 and 3 h, respectively, afterMP
treatment.
The transcriptional activation of Epo
gene by HIF-1 requires a DNA looping
mechanism that brings the HIF-1/HIF-
1-bound 3 enhancer to contact the pro-
moter of Epo gene by interacting with
CBP/p300 (Ebert and Bunn, 1998), which
serves as a coadaptor to activate an RNA
polymerase II-containing general tran-
scription factor complex to initiate gene
transcription (von Mikecz et al., 2000).
We conducted anti-CBP antibody-based
ChIP assay to examine whether MP treat-
ment recruits CBP/p300 to the Epo pro-
moter in OLGs and neurons. Figure 6E
shows that CBP association with the Epo
promoter was increased by approximately
sixfold after MP treatment for 1 h in OLGs
but not neurons, when HIF-1 and GR
were detected in the same promoter region
(Fig. 6B). This finding suggests that MP-
induced HIF-1–GR association with the
Epo gene promoter is accompanied by the
recruitment of CBP/p300 to the promoter
to trigger Epo gene transcription.
HIF-1 association with GR–HIF-1
complex is required for the Epo induction byMP treatment
MP-induced GR–HIF-1 binding to the 3 enhancer of Epo gene
correlated well with its activation of HREEpo–Luc, each requiring
binding of both HIF-1 and HIF-1 (Jiang et al., 1996). Knock-
down of HIF-1 using a specific siRNA (supplemental Fig. 1A,
available at www.jneurosci.org as supplemental material) sup-
pressed Epo expression induced by MP or CoCl2 (Fig. 7A).
Furthermore, the co-IP results show that MP significantly in-
creased HIF-1 content to the HIF-1-immunoprecipitated
complex to a similar degree as GR (Fig. 7B). Together, these
results suggest that recruitment of HIF-1 to the GR–HIF-1
complex is required for MP transactivation of Epo expression.
Structural analysis of interactions among GR, HIF-1,
HIF-1, and DNA
To understand the interaction of the HIF-1 PAS domain with
the GR–DBD and their relationship with the interaction of
HIF-1 and HIF-1, which is required for HIF-1 binding to
HRE,we applied a computationalmodeling approach to perform
a structural analysis of protein–protein interactions among GR,
HIF-1, and HIF-1. The structures of the GR–DBD and GR–
LBD were retrieved from protein data banks (PDB identification
numbers 1GDC and 1NHZ, respectively), whereas those of
HIF-1were predicted by homology to obtain a structure for the
PAS-B domain at amino acids 238-346. Based on thermal dy-
namics and intermolecular distances, the modeling results show
that the GR–DBD binds HIF-1 on the PAS-B domain while
retaining its DNA binding activity (Fig. 8A). Furthermore, the
seven residues of the GR–DBD (Gly470, His472, Tyr497, Arg498,
Gln502, Asn506, and Glu508) interact with Tyr277, Asp250,
Leu249, Glu334, Asn330, Thr297, and Asp294 of the HIF-1
PAS-B domain, respectively.Wemodeled the structure of theHIF-
1–HIF-1 complex (Fig. 8B) to explore its possible interactions
with the GR–DBD. Figure 8C shows that the HIF-1 PAS-B com-
plex interacts with the GR–DBD and HIF-1 simultaneously, pre-
serving the DNA binding activity of the GR–DBD. Results from the
protein docking analysis are summarized in Figure 8D.
Discussion
Results from the present study are the first to demonstrate that
MP protects OLGs against excitotoxicity via the HIF-1/Epo/
Bcl-xL cascade in a cell-type-specific manner under normoxic
condition. Several lines of experimental evidence support a
causal role of this cascade in MP protection against AMPA-
induced excitotoxicity in OLGs. First, exogenous Epo is effective
in protecting OLGs against AMPA-induced OLG death. Second,
both MP and Epo share a similar cytoprotective mechanism by
upregulating Bcl-xL expression in AMPA-treated OLGs. Third,
MP transactivates Epo expression in a GR-, HIF-1-, and HIF-
1-dependent manner. Fourth, the causal roles of GR, HIF-1,
and Epo are substantiated by the findings that knockdown of GR,
HIF-1, or Epo expression abolishes the cytoprotective action of
MP in OLGs. Finally, MP activation of HIF-1 occurs in a GR-
dependent manner involving stabilization of HIF-1 and com-
plex GR–HIF-1 interaction as supported by pHREEPO–Luc
studies, co-IP, ChIP assays, the yeast two-hybrid analysis, and
computer modeling of protein–protein interactions.
Figure 5. MP activation of GR–HIF-1 interaction in OLGs but not neurons. A, Immunoblotting of nuclear HIF-1 with or
without MP treatment in OLGs and neurons. B, Nuclear fractions of OLGs and neurons were immunoprecipitated with an anti-GR
antibody (IP-GR) and Western blotted with an anti-HIF-1 or anti-GR antibodies. IgG served as the loading control for the
immunoprecipitated complex for quantitative analysis of band intensity. The right shows composite results. **p	0.01 versus the
control (0 min) group, n 3. C, Domain maps of GR and HIF-1. Major domains of GR include AF-1 activation domain, DBD and
LBD; major domains of HIF-1 include bHLH, PAS-A, PAS-B, and oxygen-dependent degradation (ODD) domain. The shaded
domains in graywereused for yeast two-hybrid analysis and computermodeling for protein–protein docking.D, Yeast two-hybrid
analysis of GR–HIF-1 interaction. Left, GAL4-activation domain (GAL4AD, amino acids 768-881) hybrid and GAL4–DNA-binding
domain (GAL4BD, amino acids 1-147) hybrid. Right, Yeast colony numbers after transformation and-galactosidase activity (n
5). N.D., Not detectable.
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HIF-1, as its name implies, is induced by hypoxia. Hypoxia
does upregulate Epo expression in both OLGs and neurons.
However, MP upregulation of Epo and activation of HIF-1 are
selective for OLGs but not neurons under normoxic condition.
To the best of our knowledge, this is the first report on activation
of HIF-1 under normoxic condition by a therapeutic agentMP.
HIF-1 was increased in MP-treated OLGs (30 min) (Fig. 5A)
before the increase of GR–HIF-1 interaction (60min) (Fig. 5B),
suggesting that MP-activated GR induces HIF-1 activity via
both stabilization of and interactionwithHIF-1. It is noted that,
after MP treatment in OLGs for 30 min, both HIF-1 accumula-
tion (Fig. 5A) and GR activation (Fig. 5B, right top panel) occur,
but the GR–HIF-1 interaction was not apparent until 60 min
(Fig. 5B). Lack of an increase in GR–HIF-1 interaction at the
30 min time point reflects the time lag for activated GR to
interact with HIF-1. The sequence of events leading to inter-
action of GR and HIF-1 entails the recruitment of GR and
HIF-1 to form a protein complex as depicted in Figure 8.
More importantly, this mechanism well explains the MP pro-
tection of OLGs, but not neurons, against AMPA excitotoxic-
ity as shown in our previous studies (Lee et al., 2008). In the
present study, we have established the essential roles of GR,
HIF-1, and Epo in MP upregulation of Bcl-xL as the under-
lying mechanism of MP protection of OLGs against AMPA
toxicity normoxia (Fig. 4C,D). Activation of HIF-1 under
normoxia has been demonstrated previously in selected exper-
imental paradigms (Choi et al., 2006; Liu et al., 2007) with
RACK1 (the receptor for activated C kinase 1) and FIH-1
(factor inhibiting HIF) playing an im-
portant role. It remains to be determined
whether these factors are involved in theGR
activation of HIF-1.
In contrast to the GR–HIF-1
crosstalk under hypoxic condition in
COS7 cells engaging GR–LBD (Kodama
et al., 2003), the present study reveals an
essential role ofGR–DBD in the normoxic
mode of GR–HIF-1 interaction. In addi-
tion, the binding activity of the GR–DBD
to GRE in the GR–HIF-1–HIF-1 com-
plex is preserved according to the molec-
ular modeling results (Fig. 8A,C) that are
in agreement with the finding that muta-
tion of single amino acid (A458T) essen-
tial for the DNA binding activity of GR
failed to interrupt GR activation of HIF-1
under hypoxia condition (Kodama et al.,
2003). However, we noted another seven
amino acid residues of the GR–DBD
interacting with seven corresponding
amino acid residues in the HIF-1 PAS-B
domain. This finding raises the possibility
that different binding domains (the GR–
LBD under hypoxia vs the GR–DBD un-
der normoxia) may be separately engaged
depending on oxygen tension. Additional
studies are needed to differentiate GR–
HIF-1 interactions under oxygen-
independent versus oxygen-dependent
paradigms involving the GR–DBD or
GR–LBD, respectively.
Cell-type-specific activation of HIF-1
in oligodendrocytes, but not neurons, is
another novel finding in the present study. The mechanism of
this differential action of MP remains to be fully elucidated. Fig-
ures 5 (A and B) and 6 (B, C, and E) suggest that the critical
signaling event that differentiates oligodendrocytes from neu-
rons in responding to MP is the association of GR with HIF-1,
which occurs in oligodendrocytes but not neurons. MP activa-
tion of GR is a universal event in all the GR-expressing cell types,
including OLGs and neurons, as demonstrated in Figure 5B.
However, MP does not increase HIF-1 in neurons (Fig. 5A),
whichmatches well with the co-IP results that GR–HIF-1 inter-
action is not increased in neurons (Fig. 5B, right panel). Figure
6B–D also shows that the differential transcriptional events
in response to MP are gene specific with Trh, a typical
glucocorticoid-responsive gene, responding to MP in both neu-
rons and oligodendrocytes, in contrast to Epo, responsive to MP
only in oligodendrocytes but not neurons. The molecular mech-
anism leading to the divergence in interaction between two tran-
scription factors should be an important topic in future studies.
Furthermore, this cell-type-specific effect of MP is reflected by
preferential co-recruitment processes ofHIF-1 andGRonto the
Epo promoter/enhancer and stabilization of HIF-1 association
with the Epo promoter/enhancer in OLGs compared with neu-
rons (Fig. 6). It is noted that both Epo promoter and 3 enhancer
regions contain no sequences with appreciable similarity with
GRE (GGTACAnnnTGTTCT), suggesting that the GR–HIF-1
complex is likely to activate the Epo gene via binding to HRE but
not GRE. Thus, an apparent increase in GRE binding activity
shown by electrophoretic mobility shift assay may reflect GR
Figure 6. MP recruitment of HIF-1 and GR onto the Epo promoter and 3 enhancer in OLGs but not neurons. A, Schematic
representation of the rat Epo gene promoter and enhancer. The Epo enhancer contains an HIF-1 binding site (HRE). OLGs and
neuronswere treatedwithMP (1M) for 0, 1, and 3 h, followedby ChIP assay for the GR- andHIF-1–Epopromoter and enhancer
in OLGs (B) and neurons (C). ChIP assay of untreated cells with normal IgG served as a negative control in each set of experiments.
D, ChIP assay of the GRE-containing Trh gene promoter fragment (GRETrh) served as a GR activation control. E, OLGs and neurons
were treatedwithMP (1M) for 0, 1, and 3h, followedby ChIP assay for the CBP–Epopromoter. *p	 0.05, **p	 0.01 versus the
respective group without MP treatment; n 4.
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binding to GRE in the promoter region of
other genes, such as Trh expressed in both
OLGs and neurons, as shown in Figure
6D, than Epo gene. Importantly, the puz-
zle of why the GR–HIF-1 complex is re-
cruited to the Epo promoter before its 3
enhancer remains to be unraveled.
One of the interesting features of MP
upregulation of Epo expression is thatMP
treatment activates the expression of
HREEpo-driven reporter construct (Fig.
3), which does not contain GRE. Because
activation of HRE requires binding of
both HIF-1 and HIF-1 (Jiang et al.,
1996), the GR–HIF-1 complex will not
bind toHRE unless HIF-1 is recruited to
the complex. Our result shows that
HIF-1 is recruited to the GR–HIF-1
complex duringMP treatment, and its ex-
pression is essential for the MP-induced
Epo expression (Fig. 7). In addition, ChIP
assay results demonstrated that both GR
and HIF-1 are recruited to HRE-
containing 3 enhancer of Epo gene at 3 h.
Therefore, these findings converge to
form a conclusion that GR–HIF-1–
HIF-1 complex binding to HRE is re-
quired for the MP activation of HRE–Luc
as well as Epo gene expression. A deduced
model depicted in supplemental Figure 2
(available at www.jneurosci.org as supple-
mental material) shows that MP induces
interactions among GR, HIF-1, and
HIF-1, followed by binding to the Epo
gene promoter and 3enhancer alongwith
the CBP/p300 coadaptor to activate Epo
gene transcription. GR interaction with
HIF-1 is the key step in determining the
differential MP effects in OLGs versus
neurons. This novel signaling process
opens a new avenue to treat white matter
diseases by targeting OLGs specifically.
GCs, primarilyMP, are themainstay in
treating diseases affecting the white mat-
ter, including MS and SCI. Because of the
very lowblood–brain barrier crossing rate
(Chen et al., 1996), large doses of GCs are
needed for treating these diseases. High
doses of GCs frequently lead to serious
side effects, including suppression of im-
mune and adrenal function, loss of con-
nective tissue and bonemass, alteration of
cognitive or mental function, hyperten-
sion, glucose intolerance, and others
(McDonough et al., 2008). These side ef-
fects prevent administration of MP or
other GCs for extended periods of time to
achieve optimal therapeutic effects. Epo, a
neuroprotective cytokine, has been re-
ported to improve functional recovery in
animalmodels of demyelinating disorders
(Li et al., 2004) and SCI (Gorio et al.,
2002). However, systemic administration
Figure7. HIF-1 interactionwith theGR–HIF-1 complex is required for theMP-induced Epoexpression inOLGs.A, OLGswere
transfected with scrambled siRNA (Scr) and siArnt (for HIF-1) for 72 h, followed by incubation with MP (1M) or CoCl2 (0.4 mM)
for 12h and real-timePCRanalysis of EpomRNA. **p	0.01, ***p	0.001 versus vehicle-treated control (Ctrl); #p	0.05 versus
the MP- or CoCl2-treated group (n 3). B, Nuclear fractions of OLGs were immunoprecipitated with an anti-HIF-1 antibody
(IP-HIF-1) andWestern blotted (WB) with an anti-GR or anti-HIF-1 antibody. IgG served as the loading control for the immu-
noprecipitated complex. The right shows composite results. *p	 0.05 versus control; n 3.
Figure 8. Computer modeling of protein–protein interactions among HIF-1 PAS-B domain, GR–DBD, and HIF-1. A, Pre-
dicted structure of HIF-1 PAS-B domain docking with the GR–DBD (PDB identification number 1GDC). B, HIF-1 PAS-B domain
docking with the HIF-1 PAS-B domain. C, GR–DBD docking with the (HIF-1 PAS-B)–(HIF-1 PAS-B) complex. Insets in A show
predicted amino acid residues for GR–DBD interactionwithHIF-1PAS-B.D, Summary of themodeled protein–protein docking results.
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of Epo is also associated with serious side effects, including car-
diovascular, hematological, and other disorders (Maiese et al.,
2008). A recent Food andDrugAdministration preliminary com-
munication suggests that systemic administration of Epo in pa-
tients with acute stroke may be associated with a higher 90 d
mortality, with death related to intracerebral hemorrhage four-
fold higher in Epo-treated patients than those in the placebo
group in a clinical trial of Epo. New therapeutic strategies
directed at cell-type-specific upregulation of Epo expression
are preferred to systemic Epo or MP administration.
In conclusion, this is the first demonstration that MP protec-
tion of OLGs against excitotoxic death is mediated by the HIF-
1/Epo/Bcl-xL cascade. This MP effect is specific in OLGs, but
not neurons,mainly determined by the cell-type-specific interac-
tion between GR and HIF-1. This cell-type-specific signaling
process provides an important insight into advancing therapeutic
strategies for white matter diseases or SCI by OLG-specific tran-
scriptional regulation of Epo expression to avoid serious adverse
side effects associated with currently available therapeutic agents.
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